IOVA Stock: Price, Earnings History and SEC Filings
Iovance Biotherapeutics, Inc. (IOVA) last traded at $8.48, down 11.30% on the latest session and down 42.8% over the past month. In its most recent reported quarter (Jun 2026) earnings per share were $-0.11 against an analyst estimate of $-0.17, a beat of 35.3%.
Price data from Yahoo Finance, as of Oct 30, 2026. May be delayed.
IOVA earnings history
| Quarter | Reported | EPS | Estimate | Surprise |
|---|---|---|---|---|
| Jun 2026 | Aug 6, 2026 | $-0.11 | $-0.17 | +35.29% |
| Mar 2026 | May 7, 2026 | $-0.19 | $-0.19 | +0.00% |
| Dec 2025 | Feb 24, 2026 | $-0.18 | $-0.22 | +18.18% |
| Sep 2025 | Nov 6, 2025 | $-0.25 | $-0.29 | +13.79% |
IOVA beat the analyst EPS estimate in 3 of its last 4 reported quarters. Source: Nasdaq.
How IOVA reacts to earnings
Across its last 8 earnings releases, IOVA moved 26.6% on average the next session, in either direction. It rose after 3 of 8 reports.
| Report date | Released | Next-session move |
|---|---|---|
| 2026-08-06 | Before open | +43.09% |
| 2026-05-07 | Before open | -13.20% |
| 2026-02-24 | Before open | +30.80% |
| 2025-11-06 | Before open | +27.62% |
| 2025-08-07 | After close | -20.08% |
| 2025-05-08 | After close | -44.79% |
| 2025-02-27 | After close | -19.39% |
| 2024-11-07 | After close | -13.76% |
Based on the dates of earnings-release 8-K filings (SEC EDGAR) and daily closing prices (Yahoo Finance). Past reactions do not predict future ones.
IOVA financial history
| Fiscal year | Revenue | Net income | Free cash flow | Net margin | Diluted EPS |
|---|---|---|---|---|---|
| 2025 | $264M | -$391M | -$336M | -148.4% | $-1.09 |
| 2024 | $164M | -$372M | -$364M | -226.8% | $-1.28 |
| 2023 | $1M | -$444M | -$384M | -37345.4% | $-1.89 |
Source: annual figures from 10-K filings on SEC EDGAR. The year shown is the calendar year the fiscal year ended. Free cash flow is operating cash flow minus capital spending.
Latest SEC filings for IOVA
- 8-K · Oct 29, 2026Other events, Financial statements and exhibits
- 8-K · Oct 5, 2026Other events, Financial statements and exhibits
- 8-K · Sep 29, 2026Other events, Financial statements and exhibits
- 8-K · Aug 6, 2026Other events, Financial statements and exhibits
- 10-Q · Aug 6, 2026
- 8-K · Aug 6, 2026Results of operations, Financial statements and exhibits
- 8-K · Jul 2, 2026Other events, Financial statements and exhibits
- 8-K · Jun 10, 2026Shareholder vote, Other events, Financial statements and exhibits
- 8-K · May 7, 2026Results of operations, Financial statements and exhibits
- 10-Q · May 7, 2026
Insider filing activity
IOVA insiders filed 9 Form 4 reports in the last 90 days. A Form 4 is how directors and executives disclose purchases, sales and grants of company stock. See the individual filings on SEC EDGAR. Many Form 4 filings are routine, such as scheduled sales or option exercises, so check each filing before drawing a conclusion.
Source: SEC EDGAR.
IOVA news
- Iovance Sinks Another 11% as Baird Cuts Target to $9 After Lung Cancer DataOct 30, 2026 · tikr.com
- Iovance, A Top 1% Biotech Stock, Crashes In A Surprise Lung Cancer TwistOct 30, 2026 · finance.yahoo.com
- Iovance Biotherapeutics (IOVA) Posts 59.1% Response In Lifileucel Lung Cancer StudyOct 30, 2026 · finance.yahoo.com
- GILD Beats Q3 Earnings on HIV Strength & Trodelvy Sales GrowthOct 30, 2026 · finance.yahoo.com
- INSM Q3 Earnings Miss, Stock Soars on Sales Beat & Raised GuidanceOct 30, 2026 · finance.yahoo.com
- Is 50% Crash Risk For Iovance Stock Real?Oct 30, 2026 · trefis.com
- SLS, IOVA, IBRX Slump In October As Biotech Stocks Hold Steady: Virginia Pension Fund Raised Stakes In All 3Oct 30, 2026 · stocktwits.com
- Illumina (ILMN) Q3 Earnings Beat EstimatesOct 29, 2026 · finance.yahoo.com
About Iovance Biotherapeutics, Inc.
Iovance Biotherapeutics, Inc. (IOVA) is a US-listed public company on Nasdaq. The SEC classifies its business as Biological Products (no Diagnostic Substances). It is incorporated in DE. Its fiscal year ends in December.